Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec;113(6):798-809.
doi: 10.1111/ejh.14289. Epub 2024 Aug 22.

The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis

Roberto A S V Mazetto  1 , Sarah O N Monteiro  2 , Elísio Bulhões  3 , Maria L R Defante  2 , Vanio L J Antunes  4 , Caroline Cristine Almeida Balieiro  1 , Luanna Feitoza  5 , André L C Ferreira  6 , Amadeu M Carvalho  7 , Camila Guida  8
Affiliations
Meta-Analysis

The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis

Roberto A S V Mazetto et al. Eur J Haematol. 2024 Dec.

Abstract

Background: Chimeric antigen receptor T-cell (CAR-T) therapy has shown promise in treating hematologic malignancies, yet its potential cardiotoxic effects require thorough investigation.

Objectives: We aim to conduct a systematic review and meta-analysis to examine the cardiotoxic effects of CAR-T therapy in adults with hematologic malignancies.

Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies reporting cardiovascular outcomes, such as arrhythmias, heart failure, and reduced left ventricle ejection fraction (LVEF).

Results: Our analysis of 20 studies involving 4789 patients revealed a 19.68% incidence rate of cardiovascular events, with arrhythmias (7.70%), heart failure (5.73%), and reduced LVEF (3.86%) being the most prevalent. Troponin elevation was observed in 23.61% of patients, while NT-Pro-BNP elevation was observed in 9.4. Subgroup analysis showed higher risks in patients with pre-existing conditions, such as atrial arrhythmia (OR 3.12; p < .001), hypertension (OR 1.85; p = .002), previous heart failure (OR 3.38; p = .003), and coronary artery disease (OR 2.80; p = .003).

Conclusion: Vigilant cardiovascular monitoring is crucial for patients undergoing CAR-T therapy to enhance safety and treatment efficacy.Novelty Statements.

Keywords: CAR‐T cell; anti‐CD19; cardiotoxicity; chimeric antigen receptor T‐cell; meta‐analysis.

PubMed Disclaimer

References

REFERENCES

    1. Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: current progress and prospects. Front Immunol. 2022;13:961805. doi:10.3389/fimmu.2022.961805
    1. Pan C, Liu H, Robins E, et al. Next‐generation immuno‐oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13:29. doi:10.1186/s13045‐020‐00862‐w
    1. Huang R, Li X, He Y, et al. Recent advances in CAR‐T cell engineering. J Hematol Oncol. 2020;13:86. doi:10.1186/s13045‐020‐00910‐5
    1. Verma M, Obergfell K, Topp S, Panier V, Wu J. The next‐generation CAR‐T therapy landscape. Nat Rev Drug Discov. 2023;22(10):776‐777. doi:10.1038/d41573‐023‐00140‐7
    1. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA‐1: a multicenter study of KTE‐C19 anti‐CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285‐295.

MeSH terms

Substances

LinkOut - more resources